Dynamic Susceptibility Contrast (DSC) Perfusion MR in the Prediction of Long-Term Survival of Glioblastomas (GBM): Correlation with MGMT Promoter Methylation and 1p/19q Deletions |
Kwon, Yong Wonn
(Department of Radiology, Konkuk University Medical Center, Konkuk University School of Medicine)
Moon, Won-Jin (Department of Radiology, Konkuk University Medical Center, Konkuk University School of Medicine) Park, Mina (Department of Radiology, Konkuk University Medical Center, Konkuk University School of Medicine) Roh, Hong Gee (Department of Radiology, Konkuk University Medical Center, Konkuk University School of Medicine) Koh, Young Cho (Department of Neurosurgery, Konkuk University Medical Center, Konkuk University School of Medicine) Song, Sang Woo (Department of Neurosurgery, Konkuk University Medical Center, Konkuk University School of Medicine) Choi, Jin Woo (Department of Radiology, Konkuk University Medical Center, Konkuk University School of Medicine) |
1 | Affronti ML, Heery CR, Herndon JE 2nd, et al. Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy. Cancer 2009;115:3501-3511 DOI |
2 | Ostrom QT, Bauchet L, Davis FG, et al. Response to "the epidemiology of glioma in adults: a 'state of the science' review". Neuro Oncol 2015;17:624-626 DOI |
3 | Buckner JC. Factors influencing survival in high-grade gliomas. Semin Oncol 2003;30:10-14 DOI |
4 | Curran WJ Jr, Scott CB, Horton J, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 1993;85:704-710 DOI |
5 | DeAngelis LM. Brain tumors. N Engl J Med 2001;344:114-123 DOI |
6 | Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT, Brock C. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 1997;23:35-61 DOI |
7 | Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide forglioblastoma. N Engl J Med 2005;352:987-996 DOI |
8 | Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients withglioblastoma multiforme at first relapse. Br J Cancer 2000;83:588-593 DOI |
9 | Stupp R, Gander M, Leyvraz S, Newlands E. Current and future developments in the use of temozolomide for the treatment of brain tumours. Lancet Oncol 2001;2:552-560 DOI |
10 | Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 2016;131:803-820 DOI |
11 | Johnson DR, Guerin JB, Giannini C, Morris JM, Eckel LJ, Kaufmann TJ. 2016 updates to the WHO brain tumor classification system: what the radiologist needs to know. Radiographics 2017;37:2164-2180 DOI |
12 | Wesseling P, Capper D. WHO 2016 classification of gliomas. Neuropathol Appl Neurobiol 2018;44:139-150 DOI |
13 | Hegi ME, Diserens AC, Godard S, et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation inglioblastoma patients treated with temozolomide. Clin Cancer Res 2004;10:1871-1874 DOI |
14 | Zhao J, Ma W, Zhao H. Loss of heterozygosity 1p/19q and survival in glioma: a meta-analysis. Neuro Oncol 2014;16:103-112 DOI |
15 | Moon WJ, Choi JW, Roh HG, Lim SD, Koh YC. Imaging parameters of high grade gliomas in relation to the MGMT promoter methylation status: the CT, diffusion tensor imaging, and perfusion MR imaging. Neuroradiology 2012;54:555-563 DOI |
16 | Kim BS, Seol HJ, Nam DH, et al. Concurrent chemoradiotherapy with temozolomide followed byadjuvant temozolomide for newly diagnosed glioblastoma patients: a retrospective multicenter observation study in Korea. Cancer Res Treat 2017;49:193-203 DOI |
17 | Wesseling P, van den Bent M, Perry A. Oligodendroglioma: pathology, molecular mechanisms and markers. Acta Neuropathol 2015;129:809-827 DOI |
18 | Kim YE, Choi SH, Lee ST, et al. Differentiation between glioblastoma and primary central nervous system lymphoma using dynamic susceptibility contrast-enhanced perfusion MR imaging: comparison study of the manual versus semiautomatic segmentation method. Investig Magn Reson Imaging 2017;21:9-19 DOI |
19 | Aronen HJ, Gazit IE, Louis DN, et al. Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. Radiology 1994;191:41-51 DOI |
20 | Bag AK, Cezayirli PC, Davenport JJ, et al. Survival analysis in patients with newly diagnosed primary glioblastoma multiforme using pre- and post-treatment peritumoral perfusion imaging parameters. J Neurooncol 2014;120:361-370 DOI |
21 | Choi SH, Jung SC, Kim KW, et al. Perfusion MRI as the predictive/prognostic and pharmacodynamic biomarkers in recurrent malignant glioma treated with bevacizumab: a systematic review and a time-to-event meta-analysis. J Neurooncol 2016;128:185-194 DOI |
22 | Brown TJ, Brennan MC, Li M, et al. Association of the extent of resection with survival in glioblastoma: a systematic review and meta-analysis. JAMA Oncol 2016;2:1460-1469 DOI |
23 | Qaddoumi I, Ellison DW, Morris EB, et al. Dysembryoplastic neuroepithelial tumors and cognitive outcome: cure at a price? Cancer 2010;116:5461-5469 DOI |
24 | Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 2013;31:337- 343 |
25 | Eckel-Passow JE, Lachance DH, Molinaro AM, et al. Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med 2015;372:2499-2508 DOI |
26 | Jenkins RB, Blair H, Ballman KV, et al. A t(1;19) (q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 2006;66:9852-9861 DOI |
27 | Meng W, Jiang Y, Ma J. Is the prognostic significance of O6-methylguanine- DNA methyltransferase promoter methylation equally important in glioblastomas of patients from different continents? A systematic review with meta- analysis. Cancer Manag Res 2017;9:411-425 DOI |
28 | van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 2013;31:344-350 |
29 | Kaneshiro D, Kobayashi T, Chao ST, Suh J, Prayson RA. Chromosome 1p and 19q deletions in glioblastoma multiforme. Appl Immunohistochem Mol Morphol 2009;17:512-516 DOI |
30 | Aum DJ, Kim DH, Beaumont TL, Leuthardt EC, Dunn GP, Kim AH. Molecular and cellular heterogeneity: the hallmark of glioblastoma. Neurosurg Focus 2014;37:E11 |
31 | Stecco A, Amatuzzo P, Sponghini AP, et al. Prognostic value of relative cerebral blood volume (rCBV) in patients with recurrent glioblastoma multiforme treated with bevacizumab. J Neurosurg Sci 2016 [Epub ahead of print] |
32 | Law M, Young RJ, Babb JS, et al. Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2008;247:490-498 DOI |
33 | Sawlani RN, Raizer J, Horowitz SW, et al. Glioblastoma: a method for predicting response to antiangiogenic chemotherapy by using MR perfusion imaging--pilot study. Radiology 2010;255:622-628 DOI |
34 | Cha S, Tihan T, Crawford F, et al. Differentiation of low- grade oligodendrogliomas from low-grade astrocytomas by using quantitative blood-volume measurements derived from dynamic susceptibility contrast-enhanced MR imaging. AJNR Am J Neuroradiol 2005;26:266-273 |
35 | Blanc JL, Wager M, Guilhot J, et al. Correlation of clinical features and methylation status of MGMT gene promoter in glioblastomas. J Neurooncol 2004;68:275-283 DOI |
36 | Jenkinson MD, Smith TS, Joyce KA, et al. Cerebral blood volume, genotype and chemosensitivity in oligodendroglial tumours. Neuroradiology 2006;48:703-713 DOI |
37 | Bonekamp D, Deike K, Wiestler B, et al. Association of overall survival in patients with newly diagnosed glioblastoma with contrast-enhanced perfusion MRI: comparison of intraindividually matched T1 - and T2 (*) -based bolus techniques. J Magn Reson Imaging 2015;42:87-96 DOI |
38 | Kim SH, Choi SH, Yoon TJ, et al. Measurement of apparentdiffusion coefficient values from diffusion-weighted MRI: a comparison of manual and semiautomatic segmentationmethods. Investig Magn Reson Imaging 2015;19:88-98 DOI |
![]() |